Keryx Biopharmaceuticals About
Keryx Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company
focused on the acquisition, development and commercialization of novel pharmaceutical
products for the treatment of serious, life-threatening diseases, including diabetes
and cancer.
Sulodexide or KRX-101, for
the treatment of diabetic nephropathy, a life-threatening kidney disease
caused by diabetes,
and Perifosine or KRX-0401, for the treatment of multiple forms
of cancer. Keryx announced that it has acquired ACCESS Oncology, Inc. and
its subsidiaries or ACCESS Oncology, a cancer-focused biotechnology company. The
acquired drug portfolio includes three clinical stage compounds, designated as
KRX-0402 --inhibitor of DNA repair KRX-0403. --a novel spindle
poison in the same general class as Navelbine®, Taxol® and Taxotere®
More
on Keryx Analyst
Opinion
Analysts
Estimates